Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
News Source : PRNewswire
News Summary
- Palatin Technologies, Inc. is a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system.
- The company's obesity program is focused on MC4R selective agonists designed to enhance efficacy while improving tolerability and long-term use.
- Key IND submissions are targeted for calendar 2026 and 2027.
- Palatin will host a conference call and audio webcast on May 13, 11:00 a.m.
- ET to discuss its financial results.
Advancing MC4Rbased obesity programs for rare obesity disorders with a focus on improved tolerability and longterm use, and key IND submissions targeted in calendar 2026 and 2027 Programs [+23118 chars]
Never miss a story from us, subscribe to our newsletter